Cerebral Therapeutics™ Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy

Written By Distill

Financing Led by Granite Point Capital and Vivo Capital
Cerebral Therapeutics™ Adds Three New Members to its Board of Directors

Aurora, CO., June 20, 2018

Read Full Article

Distill https://www.distillagency.com
Previous

Cerebral Therapeutics™ Raises Series A Extension Financing to Advance Clinical-Stage Drug Device Combination Therapy to Phase 3 Readiness for Adult Refractory Epilepsy